Q-omics provides the consensus-scored PLA2G10 profile across patient tissues and cancer cell-line models. PLA2G10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PLA2G10 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PLA2G10 RNA expression shows 18,795 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where PLA2G10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G10 survival associations across molecular data types. PLA2G10 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G10 RNA expression–survival associations across cancer types. High PLA2G10 expression shows unfavorable associations in ACC, MESO and KIRP, but favorable associations in BRCA, KIRC and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PLA2G10 RNA expression.
This table summarizes PLA2G10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PLA2G10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G10 shows lower tumor expression in LUSC, COAD and READ and higher tumor expression in KIRC, BRCA and PAAD. The KIRC box plot shows higher PLA2G10 RNA expression in tumor versus normal tissue (log2 FC = +0.285, t-test p < 0.001).
This table shows molecular features associated with PLA2G10 in patient tissues and cancer cell lines. In patient samples, PLA2G10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
